Ep. 47 NSCLC Treatment: Bispecific Antibodies & EGFR Mutations with Dr. Wade Iams

Bispecific antibodies are emerging as an important therapeutic class in non-small cell lung cancer (NSCLC); but how do they work, where do they fit in clinical practice, and what should oncologists be thinking about next? In this episode of Back Table Tumor Board, Dr. Kate Baker and Dr. Wade Iams from Tennessee Oncology answer these questions and more. --- SYNPOSIS Dr. Baker and Dr. Iams discuss the evolving role of bispecific antibodies in NSCLC, covering the clinical data behind amivantamab, the practical benefits of subcutaneous vs IV administration, and key considerations for managing unique bispecific-related toxicities in real-world practice. This episode also explores emerging data in NSCLC, highlighting tarlatamab and its promising results in various treatment scenarios, including potential earlier-stage applications. --- TIMESTAMPS 00:00 - Introduction 01:14 - Recent Developments in Bispecific Antibodies03:24 - Real-World Application of MARIPOSA Trial Data04:28 - Managing Toxicities and Side Effects06:28 - CNS Disease and Efficacy of Combination Therapy08:26 - Counseling Patients on Prognosis and Treatment Options12:45 - Challenges in Rolling Out New Treatments in Rural Areas18:21- Future Directions in Non-Small Cell Lung Cancer20:57 - BiTE Therapies in Small Cell Lung Cancer35:00 - Final Thoughts --- RESOURCES MARIPOSA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2503001 FLAURA2 Trialhttp://pubmed.ncbi.nlm.nih.gov/37937763/ COPERNICUS Trialhttps://clinicaltrials.gov/study/NCT06667076 DeLLphi-304 Trialhttps://clinicaltrials.gov/study/NCT05740566?tab=results